DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,008 filers reported holding DANAHER CORPORATION in Q1 2022. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $17,438,949 | +58.6% | 70,290 | +53.4% | 0.07% | +52.3% |
| Q2 2023 | $10,994,160 | +4.8% | 45,809 | +10.0% | 0.04% | -2.2% |
| Q1 2023 | $10,493,685 | +1051.3% | 41,635 | +1112.4% | 0.04% | +800.0% |
| Q4 2022 | $911,452 | -21.6% | 3,434 | -23.8% | 0.01% | -37.5% |
| Q3 2022 | $1,163,000 | -1.6% | 4,504 | -3.4% | 0.01% | -11.1% |
| Q2 2022 | $1,182,000 | -88.1% | 4,664 | -86.3% | 0.01% | -89.0% |
| Q1 2022 | $9,953,000 | -27.8% | 33,932 | -19.0% | 0.08% | -41.8% |
| Q4 2021 | $13,791,000 | +25.1% | 41,916 | +15.8% | 0.14% | +1.4% |
| Q3 2021 | $11,022,000 | +1.4% | 36,205 | -10.6% | 0.14% | -10.9% |
| Q2 2021 | $10,871,000 | +33.8% | 40,509 | +12.3% | 0.16% | +10.6% |
| Q1 2021 | $8,122,000 | -9.7% | 36,084 | -10.9% | 0.14% | -16.6% |
| Q4 2020 | $8,991,000 | -14.7% | 40,476 | -17.3% | 0.17% | -24.6% |
| Q3 2020 | $10,536,000 | +5.5% | 48,930 | -13.4% | 0.22% | +10.9% |
| Q2 2020 | $9,990,000 | -11.9% | 56,496 | -23.5% | 0.20% | -60.5% |
| Q4 2019 | $11,341,000 | +11.3% | 73,895 | +4.7% | 0.51% | +123.6% |
| Q3 2019 | $10,191,000 | +16.3% | 70,560 | +15.1% | 0.23% | +7.0% |
| Q2 2019 | $8,759,000 | +17.9% | 61,285 | +8.9% | 0.21% | +3.9% |
| Q1 2019 | $7,431,000 | +106.0% | 56,286 | +69.6% | 0.21% | +51.5% |
| Q3 2018 | $3,607,000 | +29.3% | 33,196 | +17.4% | 0.14% | +7.9% |
| Q2 2018 | $2,789,000 | +21.6% | 28,264 | +20.6% | 0.13% | -0.8% |
| Q1 2018 | $2,294,000 | +18.7% | 23,428 | +12.5% | 0.13% | -6.6% |
| Q4 2017 | $1,933,000 | +54.0% | 20,824 | +42.4% | 0.14% | +22.5% |
| Q3 2017 | $1,255,000 | +16.9% | 14,627 | +14.9% | 0.11% | +4.7% |
| Q2 2017 | $1,074,000 | -2.4% | 12,725 | -1.1% | 0.11% | -21.5% |
| Q1 2017 | $1,100,000 | +13.4% | 12,863 | +3.3% | 0.14% | -2.2% |
| Q4 2016 | $970,000 | +4.0% | 12,456 | +4.6% | 0.14% | -2.8% |
| Q3 2016 | $933,000 | -26.5% | 11,907 | -5.3% | 0.14% | -29.4% |
| Q2 2016 | $1,270,000 | +19.1% | 12,573 | +11.9% | 0.20% | -16.9% |
| Q1 2016 | $1,066,000 | +10.1% | 11,239 | +7.8% | 0.24% | +6.6% |
| Q4 2015 | $968,000 | +115.1% | 10,426 | +98.4% | 0.23% | +110.2% |
| Q4 2013 | $450,000 | – | 5,255 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |